Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma and Other Solid Tumours
This partially randomized phase I/II trial studies the side effects and best dose of
dabrafenib, trametinib, and navitoclax and to see how well they work in treating patients
with v-raf murine sarcoma viral oncogene homolog B (BRAF) mutant melanoma or solid tumours
that have spread to other parts of the body or cannot be removed by surgery. Dabrafenib,
trametinib, and navitoclax may stop the growth of tumour cells by blocking some of the
enzymes needed for cell growth.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society